Key Takeaways
- Oncology stocks are increasingly driven by precision immunotherapy and targeted cancer treatments rather than traditional chemotherapy models.
- SELLAS Life Sciences Ltd (SLS) is a late-stage biotech focused on AML, with SLS stock heavily tied to its Phase 3 REGAL trial outcome.
- ImmunityBio Inc (IBRX) has transitioned into a commercial-stage company, with ANKTIVA driving rapid revenue growth for IBRX stock.
- SELLAS Life Sciences (SLS) offers binary clinical upside, while ImmunityBio (IBRX) represents revenue-backed expansion within oncology stocks.
Introduction
Oncology stocks remain one of the most closely watched segments in healthcare investing. Cancer treatment continues to evolve, and the shift toward immunotherapy is reshaping both clinical standards and investment frameworks.
Rather than relying solely on chemotherapy, modern oncology is increasingly focused on training the immune system to recognize and eliminate tumors. This shift has created differentiated opportunities within biotech stocks—ranging from late-stage clinical innovators to commercial-stage growth companies.
Two companies illustrate these contrasting paths: SELLAS Life Sciences (SLS), approaching a decisive Phase 3 milestone in AML, and ImmunityBio (IBRX), scaling revenue following an FDA-approved immunotherapy launch.
What Are Oncology Stocks?
Oncology stocks represent companies developing, manufacturing, or commercializing cancer therapies. This includes large pharmaceutical firms and smaller biotech innovators focused on targeted treatments.
Immunotherapy has become a defining segment within oncology. These therapies aim to activate immune cells, enhance tumor recognition, and reduce reliance on cytotoxic treatments.
High-unmet-need markets such as Acute Myeloid Leukemia (AML) and bladder cancer offer a meaningful commercial opportunity. Survival improvements in these areas can justify premium pricing and accelerated regulatory pathways.
Why Investors Consider Oncology Stocks
The global cancer burden continues to grow, supporting long-term demand for innovative therapies. Oncology drugs often command strong margins due to clinical complexity and limited alternatives.
Regulatory agencies have also introduced pathways such as Fast Track and Breakthrough Therapy designations to speed up development. This creates defined inflection points for oncology stocks.
However, valuation often hinges on clinical data and commercial execution. Investors must balance scientific potential with financial durability.
Key Drivers, Risks, and Industry Trends
The primary drivers for oncology stocks include:
- Phase 2 and Phase 3 survival data
- Regulatory approvals and label expansions
- Physician adoption and reimbursement support
Risks include clinical failure, funding pressures, competitive therapies, and pricing scrutiny.
Understanding whether a company is pre-revenue or commercial-stage is critical when evaluating risk-adjusted return potential.
SELLAS Life Sciences Ltd (SLS)
Company Overview and Business Model
SELLAS Life Sciences Ltd (SLS) is a late-stage biopharmaceutical company developing novel cancer immunotherapies.
Its lead candidate, Galinpepimut-S (GPS), targets WT1 in AML. The company is also advancing SLS009, a selective CDK9 inhibitor. SELLAS focuses on advancing promising intellectual property through late-stage development rather than building a large commercial infrastructure.
SLS stock reflects a clinical-stage biotech profile, with no current product revenue.
Financial Performance and Strategic Developments
In the third quarter of 2025, SELLAS reported a net loss of $6.8 million, or $0.06 per share, improving from the prior year. R&D expenses declined modestly, signaling disciplined capital allocation.
Following a $31 million warrant exercise, the company ended 2025 with approximately $73 million in cash and equivalents. This strengthens its runway ahead of key milestones.
The most important catalyst is the Phase 3 REGAL trial in AML. As of late December 2025, 72 of the required 80 events had occurred. Reaching the 80th event will trigger final data analysis and unblinding.
Valuation and Analyst Views
Analyst consensus remains generally positive, with a “Buy” leaning outlook. The average 12-month price target sits near $7.00, implying substantial upside from early 2026 levels around $3.50 to $3.80.
However, SLS stock trades largely as a binary bet. Approval potential in the AML maintenance market could significantly expand valuation, but failure would likely pressure shares.
Investment Suitability
SELLAS Life Sciences (SLS) may suit investors comfortable with event-driven volatility. It represents a concentrated bet on clinical success, making position sizing especially important within a diversified oncology portfolio.
ImmunityBio Inc (IBRX)
Company Overview and Business Model
ImmunityBio Inc (IBRX) is a vertically integrated immunotherapy company focused on activating natural killer (NK) cells and T-cells.
Its flagship product, ANKTIVA, is FDA-approved for certain bladder cancer patients. ImmunityBio is expanding this platform across additional indications, including lung cancer and other solid tumors.
IBRX stock reflects a company transitioning from research-focused operations to commercial execution.
Financial Performance and Strategic Developments
Preliminary fiscal 2025 revenue reached approximately $113 million, representing a 700% year-over-year increase. Q4 revenue totaled $38.3 million, up 20% sequentially.
Unit sales growth of roughly 750% highlights strong commercial traction. The company ended 2025 with about $242.8 million in cash and marketable securities.
Strategic partnerships and ongoing trials, including QUILT-2.005, support continued expansion across international markets and new indications.
Valuation and Analyst Views
With a market capitalization near $5.4 billion, ImmunityBio trades at a premium relative to current sales. Supporters argue the valuation reflects its growth trajectory and pipeline breadth.
The analyst consensus is “Strong Buy,” with an average 12-month price target around $11.80. Revenue growth remains the key metric to monitor.
Investment Suitability
ImmunityBio (IBRX) may appeal to investors seeking oncology exposure with commercial validation. While not yet profitable, recurring revenue from ANKTIVA provides a more stable foundation compared to early-stage biotech peers.
Investment Strategies for Oncology Stocks
Oncology stocks often require patience. Drug development timelines and global market expansion can span years.
Diversification across multiple oncology companies may help reduce single-asset risk. Investors may also consider balancing clinical-stage innovators like SELLAS Life Sciences (SLS) with commercial-stage growth names like ImmunityBio (IBRX).
Monitoring clinical milestones, regulatory updates, and quarterly revenue trends can provide insight into evolving risk profiles.
Conclusion
Oncology stocks remain central to long-term healthcare investing as immunotherapy reshapes cancer treatment. Precision immune activation is increasingly replacing generalized cytotoxic approaches.
SELLAS Life Sciences (SLS) represents a high-upside clinical catalyst in AML, while ImmunityBio (IBRX) demonstrates how commercial execution can translate scientific innovation into revenue growth.
For investors, the opportunity within oncology lies in understanding the difference between binary trial outcomes and scalable product adoption. Both models can create value, but each requires disciplined risk management and a long-term perspective.